HeyJaredFerdous Al-Faruque
- Indexed articles, last 90 days
- 5
- Latest publication
- Aug 18, 2026
- Outlet visibility, for Raps
- Top 1M sites
- Earliest in this view
- Jul 31, 2026
Latest articles
Stakeholders call for flexibility in guidance aimed at reducing animal testing for cancer drugs (opens the original)
Read excerpt
Welcome to another installment of This Week at FDA, your weekly source for updates – big and small – on FDA, drug, and medical device regulation, and what we’re reading from around the web. This week, FDA said it wants to conduct research into perceived barriers to enrolling women in pregnancy exposure registries, the agency announced priority review voucher fees for the next fiscal year, and it named permanent leaders to three of its product centers.
Industry groups seek clarity, flexibility in manufacturer-payor communications guidance (opens the original)
Read excerpt
Welcome to another installment of This Week at FDA, your weekly source for updates – big and small – on FDA, drug, and medical device regulation, and what we’re reading from around the web. This week, FDA said it wants to conduct research into perceived barriers to enrolling women in pregnancy exposure registries, the agency announced priority review voucher fees for the next fiscal year, and it named permanent leaders to three of its product centers.
IMDRF details key principles for regulators to adopt PCCPs (opens the original)
Read excerpt
Welcome to another installment of This Week at FDA, your weekly source for updates – big and small – on FDA, drug, and medical device regulation, and what we’re reading from around the web. This week, FDA said it wants to conduct research into perceived barriers to enrolling women in pregnancy exposure registries, the agency announced priority review voucher fees for the next fiscal year, and it named permanent leaders to three of its product centers.
This Week at FDA: Inspection reorg, acting CBER chief eyes IND reforms, and more (opens the original)
Read excerpt
Welcome to another installment of This Week at FDA, your weekly source for updates â big and small â on FDA, drug, and medical device regulation, and what weâre reading from around the web. This week, FDA said it wants to conduct research into perceived barriers to enrolling women in pregnancy exposure registries, the agency announced priority review voucher fees for the next fiscal year, and it named permanent leaders to three of its product centers.
This Week at FDA: âSimple reformâ reorg, adcomm updates, and more (opens the original)
Read excerpt
The US Food and Drug Administration (FDA) has historically developed mechanisms to expedite its review of innovative therapies. In December 2025, the agency outlined tenets of the plausible mechanism framework, intended to provide regulatory guidance when randomized controlled trials are not practical. It issued draft guidance on those tenets in February 2026. This article summarizes the FDAâs guidance on requirements for the approval of individualized therapies targeting specific conditions w
Publishing over time
Last 90 days. Choose a month to open its work.
Recurring subjects
Named in the text we hold. One piece can cover several.
Audience
Top 1M sites
For Raps, the outlet · Measured Aug 1, 2026
Website popularity band, not a count of readers or article views.
About this data
Counts cover the work we have indexed. Tone needs enough text and a confident classification. Excerpts and episode notes are not full articles or transcripts.
Identity or attribution wrong? Suggest a correction.